-
公开(公告)号：WO2011028485A2
公开(公告)日：2011-03-10
申请号：PCT/US2010/046356
申请日：2010-08-23
CPC分类号： A61K9/0024 , A61K9/0092 , A61K9/143 , A61K9/146 , A61K9/70 , A61K9/7007 , A61K38/38 , A61K38/47 , A61M1/3679 , A61M1/3687
摘要： The activation of macrophages and methods for treating cancer, bacterial pathogens and viral pathogens are disclosed. In particular, Gc protein is converted to Gc-macrophage activating factor (GcMAF), in vivo or ex vivo . The GcMAF activates macrophages which can then target cancer cells, bacterial pathogens and/or viral pathogens. Alternatively, macrophages are activated by contacting them, in vivo or ex vivo , with GcMAF. Optionally, nagalase is inactivated in a patient receiving the present macrophage activating treatment by contacting the patient's blood with a Nagalase-binding ligand immobilized on an inert medium.
摘要翻译： 公开了巨噬细胞的活化和治疗癌症，细菌病原体和病毒病原体的方法。 特别地，Gc蛋白在体内或体外转化为Gc-巨噬细胞活化因子（GcMAF）。 GcMAF激活巨噬细胞，然后可以靶向癌细胞，细菌病原体和/或病毒病原体。 或者，通过在体内或离体与GcMAF接触来激活巨噬细胞。 任选地，在接受本发明的巨噬细胞活化治疗的患者中，通过使患者的血液与固定在惰性介质上的Nagalase结合配体接触来使哒螨酮失活。
-
2.发明申请APPARATUS, SYSTEM, AND METHOD FOR CREATING IMMUNOLOGICALLY ENHANCED SPACES IN-VIVO 审中-公开用于创建体内免疫增强空间的装置，系统和方法
公开(公告)号：WO2010099515A3
公开(公告)日：2011-01-06
申请号：PCT/US2010025706
申请日：2010-02-28
申请人： KNEZEVICH CHARLES , SILVETZ ROBERT
发明人： KNEZEVICH CHARLES , SILVETZ ROBERT
CPC分类号： A61K39/0011 , A61K9/5073 , A61K35/15 , A61K35/74 , A61K38/193 , A61K38/20 , A61K39/385 , A61K2039/5152 , A61K2039/5154 , A61K2039/60 , A61L27/3804 , A61L31/005 , A61K2300/00
摘要： The present invention creates an immunologically protected/enhanced space in vivo in a mammal by removing the impact of soluble inhibitors of the mammal's immune system in a defined space within the body. Placing an antigen source within the defined protected space along with a monocyte-containing blood sample from the mammal being treated and a dendritic cell-inducing factor allows a dendritic-antigen presentation process to proceed to completion. The protected/enhanced space is created by surrounding the protected space with ligands which absorb and/or bind to one or more soluble inhibitors. The implant can be loaded with a patient's cancer cells to treat cancer.
摘要翻译： 本发明通过除去哺乳动物免疫系统的可溶性抑制剂在体内限定的空间内的影响，在哺乳动物体内产生免疫保护/增强的空间。 将抗原源与待治疗的哺乳动物的含单核细胞的血液样品一起置于限定的受保护空间内，并且树突状细胞诱导因子允许树突状抗原呈递过程进行到完成。 通过用吸收和/或结合一种或多种可溶性抑制剂的配体包围受保护空间来产生受保护/增强的空间。 植入物可以装载患者的癌细胞以治疗癌症。
-
3.发明申请APPARATUS, SYSTEM, AND METHOD FOR CREATING BIOLOGICALLY PROTECTED/ENHANCED SPACES IN VIVO 审中-公开用于在体内创建受生物保护/增强空间的装置，系统和方法
公开(公告)号：WO2012122107A2
公开(公告)日：2012-09-13
申请号：PCT/US2012027740
申请日：2012-03-05
CPC分类号： A61L31/005 , A61K35/12 , A61K35/39 , A61K35/74 , A61K39/07 , A61L31/16 , A61M1/3679 , A61M37/00
摘要： The present invention creates a biologically protected or enhanced space in vivo in a mammal to allow the mammal's immune system and/or other biological processes to function properly in order to treat autoimmune diseases. In particular, the biologically protected/enhanced space allows biological processes to occur that can therapeutically treat Type I diabetes. The biologically enhanced/protected space can also be used to promote growth of specific cells such as insulin producing islet cells of the pancreas. Microfluidic devices can also be used to remove soluble TNF receptors and autoreactive T Cells in treating autoimmune diseases. Additionally, microfluidic devices can be used to remove blood glucose, soluble insulin receptors and insulin-like growth factor (IGF) from blood in the treatment of adult onset (Type II) diabetes.
摘要翻译： 本发明在哺乳动物体内产生生物学保护或增强的空间，以允许哺乳动物的免疫系统和/或其他生物学过程适当地发挥功能，以治疗自身免疫性疾病。 特别是，生物保护/增强的空间允许发生可治疗性治疗I型糖尿病的生物过程。 生物增强/保护的空间也可以用于促进特定细胞的生长，例如产生胰岛素的胰岛细胞。 微流体装置也可用于去除可溶性TNF受体和自身反应性T细胞以治疗自身免疫性疾病。 此外，在成人发病（II型）糖尿病的治疗中，微流体装置可用于从血液中去除血糖，可溶性胰岛素受体和胰岛素样生长因子（IGF）。
-
4.发明申请APPARATUS, SYSTEM, AND METHOD FOR CREATING IMMUNOLOGICALLY ENHANCED SPACES IN-VIVO 审中-公开用于创建体内免疫增强空间的装置，系统和方法
公开(公告)号：WO2010099515A2
公开(公告)日：2010-09-02
申请号：PCT/US2010/025706
申请日：2010-02-28
CPC分类号： A61K39/0011 , A61K9/5073 , A61K35/15 , A61K35/74 , A61K38/193 , A61K38/20 , A61K39/385 , A61K2039/5152 , A61K2039/5154 , A61K2039/60 , A61L27/3804 , A61L31/005 , A61K2300/00
摘要： The present invention creates an immunologically protected/enhanced space in vivo in a mammal by removing the impact of soluble inhibitors of the mammal's immune system in a defined space within the body. Placing an antigen source within the defined protected space along with a monocyte-containing blood sample from the mammal being treated and a dendritic cell-inducing factor allows a dendritic-antigen presentation process to proceed to completion. The protected/enhanced space is created by surrounding the protected space with ligands which absorb and/or bind to one or more soluble inhibitors. The implant can be loaded with a patient's cancer cells to treat cancer.
摘要翻译： 本发明通过除去哺乳动物免疫系统的可溶性抑制剂在体内限定的空间内的影响，在哺乳动物体内产生免疫保护/增强的空间。 将抗原源与待治疗的哺乳动物的含单核细胞的血液样品一起置于限定的受保护空间内，并且树突状细胞诱导因子允许树突状抗原呈递过程进行到完成。 通过用吸收和/或结合一种或多种可溶性抑制剂的配体包围受保护空间来产生受保护/增强的空间。 植入物可以装载患者的癌细胞以治疗癌症。
-
5.发明申请
公开(公告)号：WO2012122107A3
公开(公告)日：2012-09-13
申请号：PCT/US2012/027740
申请日：2012-03-05
摘要： The present invention creates a biologically protected or enhanced space in vivo in a mammal to allow the mammal's immune system and/or other biological processes to function properly in order to treat autoimmune diseases. In particular, the biologically protected/enhanced space allows biological processes to occur that can therapeutically treat Type I diabetes. The biologically enhanced/protected space can also be used to promote growth of specific cells such as insulin producing islet cells of the pancreas. Microfluidic devices can also be used to remove soluble TNF receptors and autoreactive T Cells in treating autoimmune diseases. Additionally, microfluidic devices can be used to remove blood glucose, soluble insulin receptors and insulin-like growth factor (IGF) from blood in the treatment of adult onset (Type II) diabetes.
-
公开(公告)号：WO2011028485A3
公开(公告)日：2011-07-14
申请号：PCT/US2010046356
申请日：2010-08-23
申请人： KNEZEVICH CHARLES , SILVETZ ROBERT
发明人： KNEZEVICH CHARLES , SILVETZ ROBERT
CPC分类号： A61K9/0024 , A61K9/0092 , A61K9/143 , A61K9/146 , A61K9/70 , A61K9/7007 , A61K38/38 , A61K38/47 , A61M1/3679 , A61M1/3687
摘要： The activation of macrophages and methods for treating cancer, bacterial pathogens and viral pathogens are disclosed. In particular, Gc protein is converted to Gc-macrophage activating factor (GcMAF), in vivo or ex vivo. The GcMAF activates macrophages which can then target cancer cells, bacterial pathogens and/or viral pathogens. Alternatively, macrophages are activated by contacting them, in vivo or ex vivo, with GcMAF. Optionally, nagalase is inactivated in a patient receiving the present macrophage activating treatment by contacting the patient's blood with a Nagalase-binding ligand immobilized on an inert medium.
摘要翻译： 公开了巨噬细胞的活化和治疗癌症，细菌病原体和病毒病原体的方法。 具体而言，Gc蛋白在体内或离体转化为Gc-巨噬细胞活化因子（GcMAF）。 GcMAF激活巨噬细胞，然后巨噬细胞可以靶向癌细胞，细菌病原体和/或病毒病原体。 或者，通过使巨噬细胞在体内或离体与GcMAF接触来激活巨噬细胞。 任选地，通过使患者的血液与固定在惰性介质上的Nagalase结合配体接触，在接受本发明的巨噬细胞活化治疗的患者中使纳格拉酶失活。
-
-
-
-
-
搜索结果
6 条记录 (耗时 0.011 秒)
